Last call for registrations to Pre-Filled Syringes East Coast conference

SMi Group8 - 9 April 2019, Boston, USA.
SMi's global portfolio of events on Pre-Filled Syringes secured an audience of over 300 senior drug delivery and medical device experts over the last year. Next week will be held the 6th annual Pre-Filled Syringes East Coast conference and exhibition where industry leaders from pharmaceutical, biotech and device manufacturing, meet to get updates on medical devices advances, parenteral drug delivery, share experiences and network. Organisers encourage everyone involved in the industry not to miss out on this premier platform as only limited number of delegate places remain. For those interested in attending, contact Kieran Ronaldson on +44 (0) 20 7827 6744 or book on the Pre-Filled Syringes East Coast conference website.

Event in brief: Over 25 presentations from a mix of leading industry players and big pharma such as - Shire, Merck, FDA, Janssen, Steri-Tek, Biogen, Sanofi, Eli Lilly, Zeon and many others.

Organisations who have recently secured some of the last few remaining places includeAmerican Regent, Credence MedSystems, Dechra, Imbrium Therapeutics, Nipro Pharma Packaging, Pfizer,Purdue Pharma, Plastic Ingenuity, Sumitomo Rubber North America, Uhlmann, W.L Gore. List of attendees available on the event website.

Over 15 exhibition stands will help navigate through supplier offers: 3P Innovation, Aptar Pharma, CSS (CONNECTICUT SPRING & STAMPING),HarroHöfliger, LONSTROFF, MITSUBISHI GAS CHEMICAL, NN Life Sciences, Owen Mumford, PHC Corporation of North America, Polyplastics, RheoSense, SCHOTT, Steri-Tek, SUMITOMO RUBBER INDUSTRIES, West Pharmaceutical Services and ZEON

To register for one of the last remaining delegate places, either call Kieran Ronaldson on +44 (0) 20 7827 6744 or book online at www.pfsamericas.com

About SMi Group

The SMi Group is a highly Professional, Independent and Global company that specialises in the production of Business-to-Business Conferences, Workshops and Masterclasses. We research, create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical sectors.

We believe in bringing you the best events incorporating:

  • In-depth analysis of the subject matter
  • Tools, techniques and information to immediately benefit your business
  • High level contact with expert speakers
  • Insight into new areas, refreshing your knowledge
  • Opportunities to learn from key opinion leaders, and to engage through Q&A
  • Sessions with leading professionals and to network before, during and after event

Our management team has more than 70 years collective experience in the conference industry and our long-term success has been established by providing a reliable and expert service. This gives you the delegate, the confidence and reassurance, in knowing that we have brought you the best speakers and content for 20 years. The SMi management team plays a very active role in the day to day running of the business and events and we look forward to meeting you at an event soon!

Most Popular Now

Compound that kills drug-resistant fungi is isolat…

Antimicrobial and antifungal resistance, which describe the ability of bacteria and other pathogens to resist the effects of drugs to which they were once sensitive, is a...

Novartis receives FDA approval for Mayzent® (sipon…

Novartis today announced that the US Food and Drug Administration (FDA) has approved Mayzent® (siponimod) for the treatment of adults with relapsing forms of multiple scl...

First bacterial genome created entirely with a com…

All the genome sequences of organisms known throughout the world are stored in a database belonging to the National Center for Biotechnology Information in the United Sta...

Immune cells fighting blood cancer visualized for …

When cancer escapes the immune system, our defenses are rendered powerless and are unable to fight against the disease. Chimeric antigen receptor T cells (CAR T cells) re...

Liver, colon cancer cells thwarted by compounds de…

The plant that adds flavor, color and bitterness to beer also produces a primary compound that thwarts cancer cells, and two important derivatives of the compound do as w...

Clinical trial finds therapy to be well-tolerated …

A phase I clinical trial that set out to assess the safety of a new combination therapy for a type of aggressive brain tumour has found the treatment to be well tolerated...

FDA approves treatment for patients with a type of…

The U.S. Food and Drug Administration today approved Cimzia (certolizumab pegol) injection for treatment of adults with a certain type of inflammatory arthritis called no...

Selumetinib granted US Breakthrough Therapy Design…

AstraZeneca and MSD, Inc., Kenilworth, NJ, US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced that the US Food and Drug Administration (FDA) ha...

Boehringer Ingelheim announces FDA and EMA regulat…

Boehringer Ingelheim has filed for regulatory approval of nintedanib in patients with systemic sclerosis associated interstitial lung disease (SSc-ILD) with the FDA and E...

Novartis adds clinical and preclinical anti-inflam…

Novartis announced that it is adding to its broad portfolio of immunomodulatory medicines with the planned acquisition of IFM Tre, a subsidiary of IFM Therapeutics LLC fo...

Novartis continues transformation into a leading m…

Novartis today completed the spin-off of the Alcon eye care devices business through a dividend-in-kind distribution to holders of Novartis shares and ADRs (American Depo...

Forxiga approved in Japan for type-1 diabetes

The Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Forxiga (dapagliflozin) as an oral adjunct treatment to insulin for adults with type-1 diabetes (T...